Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921224 | 0.86 | ALDH1A1 (0.56) | HPGDALDH1A1KMT2ASIGMAR1MAPK1 | |
| SCHEMBL161104 | 0.82 | HPGD (0.69) | HPGDALDH1A1L3MBTL3KMT2AMAPK1 | |
| SCHEMBL743038 | 0.82 | HPGD (0.63) | HPGDALDH1A1HSD17B10L3MBTL3KMT2A | |
| SCHEMBL947052 | 0.81 | HPGD (0.68) | HPGDALDH1A1HSD17B10GRM5RAB9A | |
| SCHEMBL27978775 | 0.81 | HPGD (0.73) | HPGDALDH1A1L3MBTL3KMT2AMAPK1 | |
| SCHEMBL20197 | 0.81 | HPGD (0.73) | HPGDALDH1A1L3MBTL3KMT2AMAPK1 | |
| SCHEMBL28292804 | 0.79 | HPGD (0.63) | HPGDALDH1A1KMT2ASIGMAR1MAPK1 | |
| SCHEMBL4506219 | 0.79 | HPGD (0.71) | HPGDALDH1A1HSD17B10GRM5L3MBTL3 | |
| SCHEMBL23387920 | 0.78 | HPGD (0.51) | HPGDALDH1A1HSD17B10GRM5RAB9A | |
| SCHEMBL3152770 | 0.78 | HPGD (0.69) | HPGDALDH1A1HSD17B10GRM5L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| CN-102791131-A | Compounds and methods | GLAXOSMITHKLINE LLC | 2012-11-21 | — | — | CN | disclosed |
| WO-2011088031-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | HPGD 1640/4885ALDH1A1 555/4885HSD17B10 1034/4885 |
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | HPGD 3340/4885ALDH1A1 204/4885HSD17B10 361/4885 |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | HPGD 2362/4885ALDH1A1 3779/4885HSD17B10 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.